Vera Therapeutics (NASDAQ:VERA – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.30) EPS for the quarter, beating the consensus estimate of ($1.62) by $0.32, FiscalAI reports. The business had revenue of $10.28 million during the quarter, compared to analyst estimates of $3.42 million.
Here are the key takeaways from Vera Therapeutics’ conference call:
- TRUTAKNA showed strong kidney-function results in ORIGIN 3: At 104 weeks, it reduced the risk of kidney disease progression by 76% versus placebo, with kidney-function decline near a physiologic rate. Vera submitted an FDA application seeking full approval and plans an EU application in the first quarter of 2027.
- The early U.S. launch generated about 700 Patient Start Forms since the July approval, and third-quarter product revenue was $10.3 million; management said roughly half the revenue reflected demand and half inventory. The company said prescriptions span patients with both higher and lower proteinuria, while acknowledging that adoption is still at an early stage.
- Interim PIONEER results showed a 52% reduction in proteinuria from baseline at week 24 among 101 adults across broader IgA nephropathy cohorts, including patients with lower kidney function. Results in primary membranous nephropathy were preliminary, based on 16 patients.
- Spending and cash use increased as Vera funded commercialization: third-quarter net loss was $93.7 million, and operating cash use totaled $305.9 million for the first nine months of 2026. The company reported $384 million in cash and marketable securities at quarter-end and borrowed $75 million in October; additional debt capacity is subject to conditions.
Vera Therapeutics Stock Performance
NASDAQ VERA opened at $30.14 on Friday. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -5.14 and a beta of 1.07. The firm’s 50 day simple moving average is $31.70 and its 200 day simple moving average is $36.75. Vera Therapeutics has a 1 year low of $23.05 and a 1 year high of $56.05.
Insider Buying and Selling
In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total transaction of $684,500.00. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at $8,704,028. The trade was a 7.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
VERA has been the subject of a number of analyst reports. Raymond James Financial reiterated a “strong-buy” rating on shares of Vera Therapeutics in a research report on Monday, October 26th. Leerink Partners started coverage on Vera Therapeutics in a research note on Monday, October 12th. They set a “market perform” rating and a $34.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Friday. JPMorgan Chase & Co. lifted their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a report on Tuesday, September 8th. Finally, HC Wainwright cut their target price on Vera Therapeutics from $90.00 to $75.00 and set a “buy” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.43.
Read Our Latest Report on VERA
Key Vera Therapeutics News
Here are the key news stories impacting Vera Therapeutics this week:
- Positive Sentiment: Vera reported a third-quarter loss of $1.30 per share, narrower than the cited consensus estimate of $1.62, while revenue of $10.28 million exceeded estimates of $3.42 million. These results could support investor confidence, although the company’s loss remains substantial. Third-quarter earnings results
- Neutral Sentiment: HC Wainwright cut its price target from $90 to $75 but kept its “buy” rating. The revised target still implies considerable upside from the cited $30.14 share price, though the reduction may temper optimism. HC Wainwright price-target update
- Negative Sentiment: The quarterly loss widened to $1.30 per share from $1.26 a year earlier, underscoring that Vera is still reporting sizable losses despite beating estimates. Zacks quarterly results report
About Vera Therapeutics
Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.
Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.
Read More
- Five stocks we like better than Vera Therapeutics
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
